Treatment of Splenic Marginal Zone Lymphoma with Hepatitis C Virus Infection

Splenic marginal zone lymphoma (SMZL) in the setting of hepatitis C virus (HCV) infection represents a specific clinical scenario with a defined first-line treatment strategy shaped by the underlying viral comorbidity.

Clinical Scenario

This protocol applies to patients diagnosed with splenic marginal zone lymphoma who have a concurrent hepatitis C virus infection. The presence of HCV infection directly determines the treatment approach in this population.

First-Line Treatment Approach

Treatment is directed at the hepatitis C virus infection up-front. The full protocol details the specific agents, sequencing, and decision criteria that apply.

Complete regimen, eligibility criteria, and clinical pathway are available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

SMZL patients with hepatitis C infection should receive up-front anti-viral therapy.

DOI: 10.1111/bjh.19064

View source ↗